文献速递血栓与止血白血病

皮下与静脉注射阿米万他单抗联合拉泽替尼治疗难治性表皮生长因子受体突变非小细胞肺癌:III期PALOMA-3研究主要结果

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
PubMed 文献 · J Clin Oncol · 2024-06-10

PALOMA-3研究纳入418例奥希替尼和铂类化疗后进展的EGFR突变晚期NSCLC患者,随机1:1接受皮下或静脉阿米万他单抗联合拉泽替尼。皮下组药代动力学非劣效,客观缓解率30%对33%,中位无进展生存期6.1对4.3个月,总生存期显著延长(HR 0.62),输液相关反应和静脉血栓栓塞更少,给药时间更短,便利性更高。

要点

  • 皮下阿米万他单抗联合拉泽替尼在药代动力学上非劣效于静脉制剂。
  • 皮下组总生存期显著优于静脉组(HR 0.62,95%CI 0.42-0.92)。
  • 皮下组输液相关反应13%对66%,静脉血栓栓塞9%对14%,均低于静脉组。

核心结论

  • 皮下阿米万他单抗联合拉泽替尼对静脉阿米万他单抗联合拉泽替尼显示非劣效性,安全性特征一致,输液相关反应减少,便利性增加,生存期延长。

研究设计与样本

  • III期PALOMA-3研究,纳入奥希替尼和铂类化疗后进展的EGFR突变晚期非小细胞肺癌患者,随机1:1接受皮下或静脉阿米万他单抗联合拉泽替尼,共418例(皮下组206例,静脉组212例)。

主要发现

  • 皮下组对静脉组谷浓度的几何均值比在周期2第1天为1.15(90%CI 1.04-1.26),在周期4第1天为1.42(90%CI 1.27-1.61);周期2 AUC D1-D15的几何均值比为1.03(90%CI 0.98-1.09)。
  • 客观缓解率皮下组30%对静脉组33%;中位无进展生存期皮下组6.1个月对静脉组4.3个月。
  • 总生存期皮下组较静脉组显著延长(死亡风险比0.62;95%CI 0.42-0.92;名义P=0.02)。
  • 皮下组输液相关反应13%对静脉组66%,静脉血栓栓塞9%对14%。
  • 首次输注中位给药时间皮下组4.8分钟(范围0-18)对静脉组5小时(范围0.2-9.9);周期1第1天认为治疗便利的患者皮下组85%对静脉组52%,治疗结束时分别为85%对35%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. PATIENTS AND METHODS: Patients with EGFR-mutated advanced NSCLC who progressed after osimertinib and platinum-based chemotherapy were randomly assigned 1:1 to receive subcutaneous or intravenous amivantamab, both combined with lazertinib. Coprimary pharmacokinetic noninferiority end points were trough concentrations (Ctrough; on cycle-2-day-1 or cycle-4-day-1) and cycle-2 area under the curve (AUCD1-D15). Key secondary end points were objective response rate (ORR) and progression-free survival (PFS). Overall survival (OS) was a predefined exploratory end point. RESULTS: Overall, 418 patients underwent random assignment (subcutaneous group, n = 206; intravenous group, n = 212). Geometric mean ratios of Ctrough for subcutaneous to intravenous amivantamab were 1.15 (90% CI, 1.04 to 1.26) at cycle-2-day-1 and 1.42 (90% CI, 1.27 to 1.61) at cycle-4-day-1; the cycle-2 AUCD1-D15 was 1.03 (90% CI, 0.98 to 1.09). ORR was 30% in the subcutaneous and 33% in the intravenous group; median PFS was 6.1 and 4.3 months, respectively. OS was significantly longer in the subcutaneous versus intravenous group (hazard ratio for death, 0.62; 95% CI, 0.42 to 0.92; nominal P = .02). Fewer patients in the subcutaneous group experienced infusion-related reactions (IRRs; 13% v 66%) and venous thromboembolism (9% v 14%) versus the intravenous group. Median administration time for the first infusion was reduced to 4.8 minutes (range, 0-18) for subcutaneous amivantamab and to 5 hours (range, 0.2-9.9) for intravenous amivantamab. During cycle-1-day-1, 85% and 52% of patients in the subcutaneous and intravenous groups, respectively, considered treatment convenient; the end-of-treatment rates were 85% and 35%, respectively. CONCLUSION: Subcutaneous amivantamab-lazertinib demonstrated noninferiority to intravenous amivantamab-lazertinib, offering a consistent safety profile with reduced IRRs, increased convenience, and prolonged survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024. PMID: 38857463. doi:10.1200/JCO.24.01001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。